PE20030949A1 - Formulaciones en aerosol para la administracion pulmonar de medicamentos que producen un efecto sistemico - Google Patents

Formulaciones en aerosol para la administracion pulmonar de medicamentos que producen un efecto sistemico

Info

Publication number
PE20030949A1
PE20030949A1 PE2003000200A PE2003000200A PE20030949A1 PE 20030949 A1 PE20030949 A1 PE 20030949A1 PE 2003000200 A PE2003000200 A PE 2003000200A PE 2003000200 A PE2003000200 A PE 2003000200A PE 20030949 A1 PE20030949 A1 PE 20030949A1
Authority
PE
Peru
Prior art keywords
drugs
produce
pulmonary administration
aerosol formulations
systemic effect
Prior art date
Application number
PE2003000200A
Other languages
English (en)
Inventor
Gaetano Brambilla
David Ganderton
Alessandra Ferraris
Rebecca Jaine Davies
David Andrew Lewis
Brian John Meakin
Tanya Kathleen Church
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of PE20030949A1 publication Critical patent/PE20030949A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

QUE COMPRENDE UNA SOLUCION DE MEDICAMENTO EN UNA MEZCLA DE: a)PROPELENTE HIDROFLUOROALCANO QUE INCLUYE UNO O MAS HFAs SELECCIONADOS DE HFA 134 a Y HFA 227; Y, b)UNO O MAS CONSOLVENTES, COMO ETANOL EN UNA CANTIDAD DE HASTA 30% p/p O UN DERIVADO (POLI)ALCOXILADO SELECCIONADO DE ALCOHOLES POLIALCOXILADOS (TRANSCUTOL) Y ETERES Y ESTERES POLIALCOXILADOS. DONDE, LAS GOTAS DE AEROSOL LIQUIDO QUE SE ADMINISTRAN AL ACTUAR EL INHALADOR TIENEN UN TAMANO DE PARTICULA COMPRENDIDO ENTRE 0,5 um Y 2,5 um, CON UNA MEDIANA DEL DIAMETRO AERODINAMICO EN LA MASA DE APROXIMADAMENTE 1 um A 2 um Y DONDE LA FRACCION DE PARTICULAS FINAS ES DE POR LO MENOS 30%. SE REFIERE TAMBIEN A UN INHALADOR DE AEROSOL QUE CONTIENE UNA FORMULACION COMO LA DESCRITA CARACTERIZADA PORQUE LA VALVULA DEL ACCIONADOR TIENE UN DIAMETRO DE ORIFICIO ENTRE 0,20 mm Y 0,50 mm
PE2003000200A 2002-03-01 2003-02-28 Formulaciones en aerosol para la administracion pulmonar de medicamentos que producen un efecto sistemico PE20030949A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02004786A EP1340492A1 (en) 2002-03-01 2002-03-01 Aerosol formulations for pulmonary administration of medicaments having systemic effects

Publications (1)

Publication Number Publication Date
PE20030949A1 true PE20030949A1 (es) 2004-01-02

Family

ID=27675679

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000200A PE20030949A1 (es) 2002-03-01 2003-02-28 Formulaciones en aerosol para la administracion pulmonar de medicamentos que producen un efecto sistemico

Country Status (27)

Country Link
US (1) US20050129621A1 (es)
EP (2) EP1340492A1 (es)
JP (1) JP2005519094A (es)
KR (1) KR20040091050A (es)
CN (2) CN1638731A (es)
AR (2) AR038643A1 (es)
AT (1) ATE488224T1 (es)
AU (1) AU2003215597B2 (es)
BR (1) BR0303348A (es)
CA (1) CA2477879C (es)
DE (1) DE60334973D1 (es)
EA (1) EA008571B1 (es)
ES (1) ES2358293T3 (es)
GE (1) GEP20063985B (es)
HR (1) HRP20040751A2 (es)
IL (1) IL163842A0 (es)
MA (1) MA27107A1 (es)
MX (1) MXPA04008370A (es)
NO (1) NO20034874L (es)
NZ (1) NZ535019A (es)
PE (1) PE20030949A1 (es)
PL (1) PL372261A1 (es)
TN (1) TNSN04148A1 (es)
TW (1) TW200304833A (es)
UA (2) UA81238C2 (es)
WO (1) WO2003074023A1 (es)
ZA (3) ZA200406918B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
HU230804B1 (hu) * 2000-05-22 2018-06-28 Chiesi Farmaceutici S.P.A Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
ATE267591T1 (de) * 2001-07-02 2004-06-15 Chiesi Farma Spa Optimierte tobramycin-formulierung zur aerosolbildung
JP2005523905A (ja) * 2002-03-01 2005-08-11 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ホルモテロール（ｆｏｒｍｏｔｅｒｏｌ）超微細調合物
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
GB0311701D0 (en) * 2003-05-21 2003-06-25 Karib Kemi Pharm Liited Improved metered dose inhaler product
JP2007505831A (ja) * 2003-09-15 2007-03-15 ベクトゥラ・リミテッド 肺吸入による、早漏を治療するための医薬品組成物
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
IL177103A0 (en) * 2004-02-27 2006-12-10 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurized metered dose inhalers
AU2005259523B2 (en) * 2004-07-02 2011-06-09 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing TG 227 ea or TG 134 a as a propellant
RU2457832C2 (ru) * 2005-09-25 2012-08-10 Сипла Лимитед Состав на основе тровентола
US20070243262A1 (en) * 2005-12-21 2007-10-18 Hurley Kevin P Stable S-nitrosothiol formulations
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP2011534A1 (en) * 2007-07-03 2009-01-07 CHIESI FARMACEUTICI S.p.A. Metered dose inhaler actuator
PE20090907A1 (es) * 2007-07-21 2009-08-05 Boehringer Ingelheim Int Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
US8555875B2 (en) * 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
CN103052392A (zh) * 2010-07-12 2013-04-17 赛利亚医药公司 通过氨基糖苷气雾给药治疗肺部感染
EP3170846A1 (en) 2010-09-22 2017-05-24 The Board of Regents of The University of Texas System Novel block copolymer and micelle compositions and methods of use thereof
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
WO2012170677A1 (en) 2011-06-07 2012-12-13 Parion Sciences, Inc. Methods of treatment
EP2794577A4 (en) * 2011-12-20 2015-05-20 Map Pharmaceuticals Inc AUXILIARY AEROSOL FORMULATION
GB201402513D0 (en) 2014-02-13 2014-04-02 Cardiff Scintigraphics Ltd Pressurised metered dose inhalers and method of manufacture
CA3111682A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
WO2016187156A1 (en) * 2015-05-21 2016-11-24 Island Breeze Systems Ca, Llc Propellant based metered dose inhaler and food applicators and applicators
US11129848B2 (en) 2017-08-08 2021-09-28 Perricone Hydrogen Water Company, Llc Medication enhancement using hydrogen
GB201912686D0 (en) * 2019-09-04 2019-10-16 Reown Pharma Inc Pharmaceutical composition
US11123365B2 (en) 2019-11-18 2021-09-21 Perricone Hydrogen Water Company, Llc Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273835A1 (en) * 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Pharmaceutical compositions and devices for their administration
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
EP1143930B8 (en) * 1999-09-11 2008-03-19 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
CA2402020C (en) * 2000-03-09 2006-08-29 Gw Pharma Limited Pharmaceutical compositions
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
HU230804B1 (hu) * 2000-05-22 2018-06-28 Chiesi Farmaceutici S.P.A Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
JP2005523905A (ja) * 2002-03-01 2005-08-11 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ホルモテロール（ｆｏｒｍｏｔｅｒｏｌ）超微細調合物
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Also Published As

Publication number Publication date
EA200401006A1 (ru) 2005-04-28
MA27107A1 (fr) 2004-12-20
EP1480616B1 (en) 2010-11-17
AR101593A2 (es) 2016-12-28
AU2003215597B2 (en) 2008-07-31
JP2005519094A (ja) 2005-06-30
CN1638731A (zh) 2005-07-13
NZ535019A (en) 2006-09-29
PL372261A1 (en) 2005-07-11
TW200304833A (en) 2003-10-16
BR0303348A (pt) 2004-07-13
CN101502500A (zh) 2009-08-12
KR20040091050A (ko) 2004-10-27
GEP20063985B (en) 2006-12-11
MXPA04008370A (es) 2004-11-26
ZA200406918B (en) 2006-06-28
EP1340492A1 (en) 2003-09-03
DE60334973D1 (de) 2010-12-30
ZA200406917B (en) 2006-06-28
CA2477879A1 (en) 2003-09-12
ES2358293T3 (es) 2011-05-09
ZA200406919B (en) 2006-06-28
AR038643A1 (es) 2005-01-19
WO2003074023A1 (en) 2003-09-12
EA008571B1 (ru) 2007-06-29
HRP20040751A2 (en) 2004-12-31
CA2477879C (en) 2011-05-03
AU2003215597A1 (en) 2003-09-16
UA81238C2 (en) 2007-12-25
EP1480616A1 (en) 2004-12-01
US20050129621A1 (en) 2005-06-16
NO20034874L (no) 2003-12-23
ATE488224T1 (de) 2010-12-15
NO20034874D0 (no) 2003-10-31
UA80695C2 (en) 2007-10-25
IL163842A0 (en) 2005-12-18
TNSN04148A1 (en) 2007-03-12

Similar Documents

Publication Publication Date Title
PE20030949A1 (es) Formulaciones en aerosol para la administracion pulmonar de medicamentos que producen un efecto sistemico
ES2325316T3 (es) Composiciones farmaceuticas para el tratamiento del asma.
ES2687751T3 (es) Tratamiento de enfermedades respiratorias
IT1303788B1 (it) Formulazioni di aerosol medicinali.
AR018891A1 (es) Inhaladores presurizados de dosificacion medida y formulaciones farmaceuticas en aerosol
PE20011323A1 (es) Formulaciones farmaceuticas en solucion estable para inhaladores presurizados con medicion de dosis
AR009231A1 (es) Formulaciones en aerosol de formoterol.
CO4940408A1 (es) Composicion de aerosol farmaceutico
MX9300620A (es) Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona.
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
JP2005512691A (ja) 用量計量型吸入器
AR015820A1 (es) Particulas de budesonida, composicion farmaceutica, uso de dichas particulas para la fabricacion de medicamentos, metodo para el tratamiento de untrastorno respiratorio y proceso para la preparacion de las particulas
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
JO2381B1 (en) Formulation containing anticholinergic drug for the treatment of chronic obstructive pulmonary disease
HU226694B1 (en) Medicinal aerosol products containing ciclesonide
IT1317720B1 (it) Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
PE20011271A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
DK1684719T3 (da) Alfa-1-antitrypsin-sammensætninger og behandlingsfremgangsmåder, der anvender sådanne sammensætninger
US20100227008A1 (en) Salicylic acid acne spray formulations and methods for treating acne with same
Lewis et al. New actuators versus old: reasons and results for actuator modifications for HFA solution MDIs
MX9301410A (es) Composiciones farmaceuticas en aerosol conteniendo la sustancia activa flezelastina y estructuras afines.
AU2003215588A1 (en) Aerosol formulations containing esters of 3,17-dihydroxy oestratriene derivatives for pulmonary delivery
TH65855A (th) สูตรผสมชนิดละอองลอยของยาสำหรับการให้ทางปอดเพื่อให้เกิดผลทั่วร่างกาย

Legal Events

Date Code Title Description
FC Refusal